These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1437154)

  • 1. Bone marrow-transforming activity of linker insertion mutants of Abelson murine leukemia virus.
    Hevezi P; Alin K; Rees-Jones R; Goff SP
    Oncogene; 1992 Nov; 7(11):2323-8. PubMed ID: 1437154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
    Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
    J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
    Hevezi P; Alin K; Goff SP
    Oncogene; 1993 Sep; 8(9):2413-23. PubMed ID: 8361756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
    Dyall-Smith D; Cory S
    Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation within the kinase domain of v-abl gene responsible for temperature-sensitive colony-forming ability in soft agar.
    Soma T; Tsukada S; Oka Y; Kishimoto T; Sugiyama H
    Virology; 1993 Apr; 193(2):967-70. PubMed ID: 8460498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multistage progression of Abelson virus-infected murine pre-B-cells to the tumorigenic state.
    Palumbo GJ; Ozanne BW; Kettman JR
    Cancer Res; 1990 Mar; 50(6):1917-23. PubMed ID: 2155061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming pathways activated by the v-Abl tyrosine kinase.
    Shore SK; Tantravahi RV; Reddy EP
    Oncogene; 2002 Dec; 21(56):8568-76. PubMed ID: 12476303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.
    Mainville CA; Parmar K; Unnikrishnan I; Gong L; Raffel GD; Rosenberg N
    J Virol; 2001 Feb; 75(4):1816-23. PubMed ID: 11160680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.
    Rees-Jones RW; Goff SP
    J Virol; 1988 Mar; 62(3):978-86. PubMed ID: 2828693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of the LTR of Abelson murine leukemia virus does not alter the cell type of virally induced tumors.
    Green PL; Kaehler DA; McKearn J; Risser R
    Oncogene; 1988 Jun; 2(6):585-92. PubMed ID: 2838788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus and cell requirements for Friend virus granulocytic leukemogenesis in long-term bone marrow cultures of NIH swiss [N:NIH(S)] mice.
    Greenberger JS; Newburger PE; Lipton JM; Moloney WC; Sakakeeny MA; Jackson PL
    J Natl Cancer Inst; 1980 Apr; 64(4):867-78. PubMed ID: 6928998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrested development: understanding v-abl.
    Kerr LD
    Bioessays; 1994 Jul; 16(7):453-5. PubMed ID: 7945272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of v-Abl transformation by p53 and p19ARF.
    Cong F; Zou X; Hinrichs K; Calame K; Goff SP
    Oncogene; 1999 Dec; 18(54):7731-9. PubMed ID: 10618713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of flat revertants isolated from cells transformed by Abelson murine leukemia virus (Ab-MuLV).
    Oka T; Yutsudo M; Inoue H; Higuchi F; Hakura A
    J Cell Physiol; 1990 Dec; 145(3):428-33. PubMed ID: 1703165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
    Morrison LE; Boehmelt G; Enrietto PJ
    Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines.
    Muljo SA; Schlissel MS
    Nat Immunol; 2003 Jan; 4(1):31-7. PubMed ID: 12469118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.